Pseudotropine

Pseudotropine at a Glance

Pseudotropine, or tropan-3β-ol (ψ-tropine), is a small tropane amino-alcohol — the 3β epimer of tropine. The two molecules are identical except for the orientation of a single hydroxyl group on the tropane ring: tropine carries it in the 3α (axial) position, pseudotropine in the 3β (equatorial) position. That one difference is the whole point of this molecule.

Pseudotropine has little pharmacology of its own. Its importance is biosynthetic: it is the branch-point precursor to the calystegines — a family of polyhydroxylated nortropane sugar-mimics that inhibit glycosidase enzymes — and to a set of pseudotropine-esterified tropanes. The 3α-branch, built from tropine, leads instead toward the well-known anticholinergic alkaloids atropine and hyoscyamine ^{1,3Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →}.

In ashwagandha (Withania somnifera) it is a trace constituent, one of several minor tropane-type alkaloids well below the plant’s defining withanolides in abundance and importance. It is not why anyone takes ashwagandha, and it has no standalone human evidence base.

The 3β-Epimer Branch Point: Pseudotropine → Calystegines vs. Tropine → Atropine/Hyoscyamine

This is the reason the molecule earns a page. Tropane biosynthesis funnels through a single ketone, tropinone, which is then reduced by two different, opposite-facing enzymes — a metabolic fork where the stereochemistry of one reduction decides the plant’s entire downstream alkaloid profile ^{1,2Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 2Wu N et al. · 2019Biochemical characterization reveals the functional divergence of two tropinone reductases from Przewalskia tanguticaView study →}.

• Tropinone reductase I (TR-I) reduces tropinone to tropine — the 3α alcohol. Tropine is then esterified with tropic acid and elaborated toward hyoscyamine and atropine, the classic anticholinergic tropanes ^{1Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →}.
• Tropinone reductase II (TR-II) reduces the same substrate to pseudotropine — the 3β alcohol. Pseudotropine is the committed entry point to the calystegines (polyhydroxy nortropanes) ^{1,3Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →}.

Both enzymes are short-chain dehydrogenases/reductases evolved from a common ancestor, and their opposite stereospecificity is set by their substrate-binding sites — a textbook example of how a small active-site difference partitions a shared precursor into two chemically and pharmacologically distinct alkaloid families ^{4,5Reference 4Nakajima K et al. · 1993Two tropinone reductases with different stereospecificities are short-chain dehydrogenases evolved from a common ancestorView study →Reference 5Nakajima K et al. · 1994Opposite stereospecificity of two tropinone reductases is conferred by the substrate-binding sitesView study →}. Functional evidence for the split is direct: in potato, silencing TR-II strongly reduces calystegine accumulation, confirming that the pseudotropine (3β) branch — not the tropine (3α) branch — feeds the calystegines ^{6Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}.

The practical takeaway: α vs. β at a single carbon is the switch. Pseudotropine is the marker for the sugar-mimic (calystegine) side of tropane metabolism; tropine is the marker for the deliriant/anticholinergic side.

What It's Used For

Pseudotropine is best understood as a biosynthetic intermediate, not a bioactive drug. The honest evidence picture is that the isolated molecule has essentially no direct human or animal pharmacology; what literature exists is enzymology and pathway biology, with any downstream bioactivity belonging to its products (the calystegines), not to pseudotropine itself.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Note the unusual shape here: the best-evidenced row is a biochemical role, not a therapeutic use, and the pharmacology row credits pseudotropine’s products, not the molecule.

01Biosynthetic branch-point precursor (calystegines)Shaky42%Well-documented enzymology: TR-II → pseudotropine → calystegines ^{1,4,6Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 4Nakajima K et al. · 1993Two tropinone reductases with different stereospecificities are short-chain dehydrogenases evolved from a common ancestorView study →Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}

02Glycosidase inhibition (via its calystegine products)Shaky18%In-vitro inhibition of human α-glucosidases — by calystegines, not pseudotropine ^{3,7Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →Reference 7Brock A et al. · 2008The functional divergence of short-chain dehydrogenases involved in tropinone reductionView study →}

03Direct / standalone pharmacologyShaky4%No isolate human/animal data; not used as a drug or supplement

Mechanisms

The load-bearing point is negative space: pseudotropine’s own “mechanism” is being a good substrate for TR-II and a good precursor for calystegines. It is not a receptor drug.

Pharmacokinetics

No dedicated human pharmacokinetic data exist for isolated pseudotropine — it has not been developed or dosed as a drug, so absorption, oral bioavailability, metabolism and half-life are uncharacterised. What is documented is the biochemical fate within the plant: pseudotropine is typically consumed as an intermediate, hydroxylated onward to calystegines rather than accumulated, which is part of why it is usually a trace species ^{1,6Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}. For the downstream calystegines, in-vitro work suggests poor systemic availability (no measurable transport across the Caco-2 intestinal model), which further undercuts any assumption of systemic activity from dietary exposure ^{3Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →}.

Clinical Trials

There are no clinical trials of isolated pseudotropine — none completed, planned or terminated. It is not a clinical entity. The only human-relevant experimental work on this branch concerns the calystegines as dietary glycosidase inhibitors, and that remains preclinical/in-vitro ^{3,7Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →Reference 7Brock A et al. · 2008The functional divergence of short-chain dehydrogenases involved in tropinone reductionView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

Almost everything known about pseudotropine comes from enzyme and pathway studies in the plant — cloned tropinone reductases, isotope-labelled precursor feeding, and transgenic knockdowns — rather than from dosing the purified molecule in animals or people ^{1,4,6Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 4Nakajima K et al. · 1993Two tropinone reductases with different stereospecificities are short-chain dehydrogenases evolved from a common ancestorView study →Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}. There is no isolate pharmacology to weigh against whole-plant data, because the isolate has not been studied as a bioactive. Where a downstream effect is shown (calystegine glycosidase inhibition), it uses compounds purified from plants (potato) and tested in vitro — and, critically, tests a different molecule than pseudotropine ^{3,7Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →Reference 7Brock A et al. · 2008The functional divergence of short-chain dehydrogenases involved in tropinone reductionView study →}. The honest summary: this is a pathway molecule characterised biochemically, not a candidate therapeutic characterised pharmacologically.

Its Role in Plants

In the plant, pseudotropine sits at a metabolic decision point. After putrescine is methylated and cyclised to the N-methyl-Δ¹-pyrrolinium cation and built up to tropinone, tropinone reductase II reduces it to pseudotropine, committing carbon toward the calystegines rather than toward the tropic-acid esters (hyoscyamine/atropine) that TR-I’s product feeds ^{1,2Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 2Wu N et al. · 2019Biochemical characterization reveals the functional divergence of two tropinone reductases from Przewalskia tanguticaView study →}.

The calystegines that pseudotropine builds are thought to serve ecological and physiological roles as sugar-mimic glycosidase modulators — they accumulate in roots and sprouting tubers of Solanaceae such as potato, though their precise in-planta function (defence, carbohydrate signalling, rhizosphere interactions) is not fully settled ^{3,6Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}. That pseudotropine is usually present only in trace amounts is consistent with its status as a consumed intermediate on the way to these end-products ^{1Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →}.

These are plant-biochemistry roles and should not be read as human pharmacology.

Prevalence in Nature

Pseudotropine occurs across the tropane-producing families — chiefly the Solanaceae (nightshades) and Convolvulaceae (bindweeds/morning glories) — the same lineages that make tropine and, on the other branch, the calystegines ^{1,3Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 3Jocković N et al. · 2013Inhibition of human intestinal α-glucosidases by calysteginesView study →}. In practice it is reported at low, often trace concentrations, because it is an intermediate rather than a stored end-product; broad surveys of tropane alkaloids and calystegines across food and medicinal plants place it among the minor pathway constituents rather than the accumulating alkaloids ^{9Reference 9Romera-Torres A et al. · 2018Analytical methods, occurrence and trends of tropane alkaloids and calystegines: an updateView study →}.

In ashwagandha (Withania somnifera) it is one of several minor tropane-type alkaloids (alongside tropine, isopelletierine and anaferine), far below the plant’s characteristic withanolides in abundance. The tropane pathway is genuinely present in the plant — a tropinone reductase from W. somnifera has been cloned and shown to catalyse the tropinone→tropine step, with expression even in aerial tissues — which establishes the biosynthetic machinery for these trace tropanes, pseudotropine included ^{8Reference 8Kushwaha AK et al. · 2013Tropine forming tropinone reductase gene from Withania somnifera (Ashwagandha): biochemical characteristics of the recombinant enzyme and novel physiological overtones of tissue-wide gene expression patternsView study →}. Reliable quantitative figures for pseudotropine specifically in ashwagandha are not well established; that hole is logged in this compound’s gaps tracker.

Discovery & Synthesis

Pseudotropine entered the literature as the 3β (endo) stereoisomer of tropine, distinguished from tropine in the classical tropane chemistry that grew out of nineteenth- and early-twentieth-century work on atropine and cocaine. Its modern biochemical identity — as the specific product of a second, stereochemically opposite tropinone reductase — was pinned down when Nakajima, Hashimoto and Yamada characterised the two tropinone reductases (TR-I and TR-II) in the early 1990s, showing they are common-ancestor short-chain dehydrogenases whose opposite stereospecificity is dictated by their substrate-binding sites ^{4,5Reference 4Nakajima K et al. · 1993Two tropinone reductases with different stereospecificities are short-chain dehydrogenases evolved from a common ancestorView study →Reference 5Nakajima K et al. · 1994Opposite stereospecificity of two tropinone reductases is conferred by the substrate-binding sitesView study →}. Chemically, pseudotropine is readily obtained by reduction of tropinone (the two C3 epimers, tropine and pseudotropine, differ only in which face is reduced), and its pathway role has since been reconstructed and manipulated by metabolic engineering in hosts such as potato, where tropinone-reductase and precursor genes were altered to probe calystegine formation ^{1,6Reference 1Kim N et al. · 2016Tropane and granatane alkaloid biosynthesis: a systematic analysisView study →Reference 6Küster N et al. · 2017Potato plants with genetically engineered tropane alkaloid precursorsView study →}. No standalone commercial manufacture of pseudotropine as a product is documented — its interest is as a research intermediate and pathway marker.

Patents: not yet researched.

Toxicity & Safety

Pseudotropine carries a low flag. It is not an anticholinergic — it lacks the tropic-acid ester that makes hyoscyamine and atropine dangerous — and it is present in the source plants and foods only in trace amounts, as a biosynthetic intermediate. There is no documented syndrome of pseudotropine poisoning, and no isolate toxicology package characterising it in the way the anticholinergic tropanes are characterised. That said, absence of a toxicology dataset is not the same as proven safety.

Safety at a Glance

✅ Low / no toxicity

• Not anticholinergic. Unlike its 3α-epimer’s descendants (atropine, hyoscyamine), pseudotropine has no established muscarinic-receptor activity — it is a plain amino-alcohol precursor.
• Trace, incidental exposure. In ashwagandha and nightshade-family foods it occurs at trace levels as a pathway intermediate, not as an accumulating active.
• Company it keeps. The plants that make pseudotropine (nightshades, datura, etc.) also make genuinely poisonous anticholinergic tropanes; risk from those plants is about the other alkaloids, not pseudotropine.
• No isolate toxicology. There is no dedicated safety, genotoxicity, or reproductive dataset for purified pseudotropine; do not read the low flag as a positive safety demonstration.

Dosage

There is no established or studied human dose for isolated pseudotropine. It is not a supplement and not a medicine — it is a trace biosynthetic intermediate, and human exposure is incidental (as a minor constituent of nightshade-family plants and foods). No therapeutic dose has been defined because no therapeutic use exists. Nothing here should be read as a dosing recommendation.

References

1. Kim N, Estrada O, Chavez B, Stewart C Jr, D’Auria JC (2016). Tropane and granatane alkaloid biosynthesis: a systematic analysis. Molecules. https://pubmed.ncbi.nlm.nih.gov/27845728/
2. Wu N, Jian D, Xiang M, Chen M, Lan X, Liao Z, Liu X (2019). Biochemical characterization reveals the functional divergence of two tropinone reductases from Przewalskia tangutica. Biotechnology and Applied Biochemistry. https://pubmed.ncbi.nlm.nih.gov/31051047/
3. Jocković N, Fischer W, Brandsch M, Brandt W, Dräger B (2013). Inhibition of human intestinal α-glucosidases by calystegines. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/23697377/
4. Nakajima K, Hashimoto T, Yamada Y (1993). Two tropinone reductases with different stereospecificities are short-chain dehydrogenases evolved from a common ancestor. Proceedings of the National Academy of Sciences USA. https://pubmed.ncbi.nlm.nih.gov/8415746/
5. Nakajima K, Hashimoto T, Yamada Y (1994). Opposite stereospecificity of two tropinone reductases is conferred by the substrate-binding sites. Journal of Biological Chemistry. https://pubmed.ncbi.nlm.nih.gov/8163465/
6. Küster N, Rosahl S, Dräger B (2017). Potato plants with genetically engineered tropane alkaloid precursors. Planta. https://pubmed.ncbi.nlm.nih.gov/27783159/
7. Brock A, Brandt W, Dräger B (2008). The functional divergence of short-chain dehydrogenases involved in tropinone reduction. The Plant Journal. https://pubmed.ncbi.nlm.nih.gov/18221363/
8. Kushwaha AK, Sangwan NS, Trivedi PK, Negi AS, Misra L, Sangwan RS (2013). Tropine forming tropinone reductase gene from Withania somnifera (Ashwagandha): biochemical characteristics of the recombinant enzyme and novel physiological overtones of tissue-wide gene expression patterns. PLoS One. https://pubmed.ncbi.nlm.nih.gov/24086372/
9. Romera-Torres A, Romero-González R, Martínez Vidal JL, Garrido Frenich A (2018). Analytical methods, occurrence and trends of tropane alkaloids and calystegines: an update. Journal of Chromatography A. https://pubmed.ncbi.nlm.nih.gov/29886001/

View all 9 references▾